Dec 08

Revolutionary test predicts heart attack or stroke seven years in advance

Results of a 2009 study conducted by researchers at the Mayo Clinic and Tufts University Hospital reported that the EndoPAT test is “highly predictive” of a major cardiac event, such as a heart attack or stroke, for people who are considered at low or moderate risk based on their Framingham Risk Score (FRS).

In this Mayo Clinic study, published in the Journal of the American College of Cardiology, Amir Lerman, M.D., a cardiologist at Mayo Clinic and senior author of the study, and other researchers, used an EndoPAT to measure the endothelial health of 270 patients between the ages of 42 and 66 and followed their progress between 1999 and 2007.

These patients already knew that they had low-to-medium risk of experiencing a major adverse cardiac event, or MACE, based on their FRS. Some of their risk factors included high blood pressure, high cholesterol, obesity, and a family history of heart disease.

The study results indicate that those patients who tested positive for endothelial disfunction had a much higher rate of major adverse cardiac events (MACE) than those whose endothelial function scored above the ‘safe’ line.

Endo-PAT2000 is manufactured by Itamar Medical.